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Integrins are a large group of transmembrane proteins that 
anchor the cell to the extracellular matrix (ECM) or other 
cells. Upon binding, integrins remodel the ECM by 
inducing the expression of certain proteases. Integrins 
control cellular proliferation, migration, and invasion. 
Whereas in some cases integrins can mediate these eﬀ  ects 
on their own, they usually signal in the context of growth 
factor or cytokine receptors [1]. Ligand binding to integrin 
controls adhesion-dependent proliferation, whereas 
unligated integrins enhance apoptotic pathways [2]. Th  is  is 
one reason why dysregulated integrin expression or 
downstream signaling pathways can be observed in almost 
all forms of cancer, and integrin levels often determine the 
aggressiveness or propensity to metastasize.
Migration, invasion, and proliferation of synovial cells 
are major problems in rheumatoid arthritis (RA) [3]. Th  is 
debilitating disease is characterized by an inﬂ  amed 
synovial tissue with a massive inﬂ  ux of immune cells and 
an inﬂ  ated synovial lining consisting mainly of synovial 
ﬁ   broblasts (SFs) and macrophages that adhere to the 
adjacent ECM. Th  ese SFs are highly proliferative and 
contribute signiﬁ  cantly to cartilage and bone destruction. 
In some aspects, they can be considered ‘tumor-like’ as 
SFs are resistant to many apoptotic pathways, show 
increased proliferation, and produce high amounts of 
matrix metalloproteinases (MMPs) because of dysregu  la-
tion of the transcription factors AP-1, p53, and nuclear 
factor-kappa-B (NF-κB) [4]. Fibroblasts, macrophages, 
but also endothelial cells in synovial tissue show high 
levels of integrin expression [5]. In RA, not only integrins 
but also their ligands (for example, ﬁ  bronectin  and 
collagen as well as their degradation products) are up-
regulated [6]. Th  is ‘overstimulation’ of cells by integrin-
mediated signals increases basal secretion of pro-
inﬂ  ammatory cytokines like interleukin-6 (IL-6) and IL-8 
but also levels of various MMPs [7-9].
Th  is review introduces the predominant integrins 
expressed on synovial cells along with their binding 
partners and demonstrates their signiﬁ  cance in disease 
progression. We focused mainly on the β1, β3, and β5 
integrins because altered levels of their ligands and 
respective integrins themselves are one major factor that 
fuels the destruction of cartilage in RA. Although 
integrins inﬂ  uence RA signiﬁ  cantly, only a few reviews 
that address integrins in RA have been published. A 
Medline search for ‘integrins’ and ‘arthritis’ yielded 108 
(compared with ‘integrins’ and ‘cancer’ with over 1,200 
reviews) reviews, most of which outlined single integrins 
or cell types. Two reviews in 1993 and 1995 – by Postigo 
and colleagues [10] and Liao and Haynes [11], respec-
tively – were the last comprehensive articles describing 
the inﬂ   uence of integrins on the pathogenesis of RA. 
Both articles, however, failed to describe the intricacies 
in integrin biology, from the generation of integrin 
ligands from the ECM to the subsequent triggering of 
integrin signaling cascades that ﬁ  nally lead to the genera-
tion of pro-inﬂ   ammatory factors and cartilage 
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that demonstrates the whole integrin machinery in 
arthritis, including ligands, receptors, and eﬀ  ector cells.
Integrin biology
A cell needs to sense the composition of the extracellular 
environment to elicit appropriate responses. Integrins, a 
family of heterodimeric proteins, serve as sensors of the 
ECM. Integrins consist of an α subunit that determines 
ligand speciﬁ   city and a β subunit that initiates intra-
cellular signaling events. Whereas most integrins bind 
almost exclusively to ECM molecules, β2 hetero  dimers 
bind other adhesion molecules, mediate cell-cell contacts, 
and are important components of the immune system. In 
contrast to the β2 integrin, which is expressed only on 
immune cells, other β subunits have a much more diverse 
expression. In the synovium, ﬁ  broblasts, macrophages, 
and endothelial cells are just a few examples of cells that 
express the β1, β3, and β5 subunits. Th  e ECM-binding 
integrins mediate cellular processes such as adhesion, 
migration, tissue invasion, and chemotaxis but also 
cytokine and MMP production.
Within the protein sequences of ﬁ  bronectin, collagen, 
and vitronectin, integrins bind to arginine-glycine-
aspartic acid (RGD) motives. Interaction with the RGD 
sequence is an important switch for integrin activation 
and subsequent cellular changes. Integrins can transduce 
signals from outside the cell to the interior and vice versa, 
allowing the cell to respond dynamically to a wide variety 
of stimuli. Growth factors, hormones, and cytokines as 
well as the composition of the ECM are able to modulate 
integrin signaling and aﬃ   nity [12]. When integrins are 
activated by ligands, several signaling events are initiated. 
Besides the focal adhesion kinase (FAK), the mitogen-
activated protein kinase (MAPK) pathway, the phos-
phatidyl  inositol 3-kinase (PI3K), and c-Jun N-terminal 
kinases (JNKs) are activated [13]. Growth factors and 
cytokines employ the same signaling pathways as 
integrins, demonstrating an intricate interplay between 
the two. Integrins are linked to the cytoskeleton by 
coupling to adaptor proteins such as vinculin and talin. 
Th   erefore, changes in integrin activation lead to changes 
in the actin cytoskeleton, a prerequisite for adhesion, 
migration, and invasion on ECMs.
Integrin knockouts and related pathologies
Given that various integrin combinations recognize the 
same ECM molecule (for example, ﬁ  bronectin is recog-
nized by α4β1, α5β1, ανβ1, ανβ3, and α3β1 and weakly by 
others), one would expect some redundancy in integrin 
function. In fact, this is the case when collagen-binding 
integrin subunits α1 or α2 are knocked out. When α1 is 
knocked out, corresponding mice show decreased vascu-
la  ri  zation, and isolated endothelial cells from these 
animals show reduced proliferation whereas α2 knock-
outs demonstrate only a subtle phenotype. Th   e picture is 
diﬀ   erent when regarding the knockout of ﬁ  bronectin-
binding integrin subunits. Knockout of either integrin α3, 
α4, α5 or αν is lethal during embryogenesis and respec-
tive mice die shortly after birth. Also, the ﬁ  bronectin-
binding integrins have a more tissue-speciﬁ  c distribution 
than collagen-binding integrins, making target cells more 
susceptible to speciﬁ  c knockouts.
Besides having a role in development, integrin muta-
tions lead to a variety of other defects. Leukocyte adhe-
sion deﬁ  ciency type 1 (LAD-1) is an autosomal recessive 
disorder based on point mutations within the β2 integrin, 
resulting in either its absence on the cell surface or the 
inability to associate with the corresponding α subunit. 
Th   is leads to reoccurring bacterial infections, suggesting 
an impaired function of macrophages and neutrophils.
Another autosomal recessive (although an autoimmune 
form exists) disease is the Glanzmann thrombasthenia, in 
which the platelet integrin αIIbβ3 fails to bind to 
ﬁ   brinogen and ﬁ  brin.  Th  is step is important to form 
blood clots after injury, and failure to do so leads to 
prolonged bleeding.
Integrins are also involved in the generation and 
perpetuation of cancer. In several tumors, expression of 
speciﬁ  c integrin subunits is associated with malignancy. 
In melanoma, increased expression of ανβ3 and α5β1 
promotes vertical growth and lymph node metastasis. In 
non-small-cell lung carcinoma, high α5β1 levels predict 
decreased patient survival. In general, alterations in 
integrin activation or expression promote tumor growth 
and metastasis. However, in some cases (for example, 
α2β1 in breast cancer), integrins can be protective by 
decreasing cell dissemination [14]. Th   is integrin increases 
diﬀ  erentiation of epithelium and enhances ECM binding, 
thus decreasing migration.
Integrins in synovial tissue
When the integrin distribution in the synovial tissue is 
analyzed, several factors need to be considered. First, 
integrin expression and function diﬀ  er depending on cell 
type. Second, the location of the cell is important as 
expression levels diﬀ  er at the synovial lining compared 
with the sublining. Every cell in the synovial tissue 
expresses a speciﬁ   c subset of integrins, depending on 
lineage and origin. Several groups have investigated 
synovial tissue samples and isolated cells to study integrin 
expression. Th  e integrin subunit β1 is most widely ex-
pressed since it can be found on macrophages, lympho-
cytes, endothelial cells, and ﬁ   broblasts [5,15,16]. Th  e 
ﬁ  bronectin receptor α5β1 and the laminin receptor α3β1 
were also found on every synovial cell type, whereas 
α4β1, which besides ﬁ  bronectin also binds VCAM-1, was 
found only on lymphocytes. Endothelial cells and 
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the vitronectin receptor ανβ3 [17]. In synovial tissue, 
integrin expression also depends on the location of the 
particular cell. Expression of most integrins is similar 
throughout the synovial tissue but is diﬀ   erent at the 
synovial lining layer [5]. Th   is is the area where synovial 
cells adhere to cartilage and activated ﬁ  broblasts  and 
macrophages degrade ECM and invade cartilage. Th  e 
laminin receptor α6β1 is expressed by ﬁ  broblasts at the 
lining layer but not by macrophages, which usually 
express this receptor [18]. At the synovial lining, we 
found an increase in α5, αν, and β1 integrin levels 
compared with the sublining area. Th   is clearly indicates 
that increased integrin expression is associated with a 
more ‘destructive’ phenotype of the corresponding cell.
Figure  1 depicts the integrin-ligand interactions and 
their consequences (for example, proliferation and secre-
tion of pro-inﬂ   ammatory mediators) described in the 
next three sections. Th   e most important cell types (ﬁ  bro-
blasts, endothelium, T cells, B cells, macrophages, and 
Th   17 cells), including their individual reaction to integrin 
engagement, are depicted (Figure 1). Th   e individual inte-
grin levels on each cell type are presented in Table 1. Th  is 
table reﬂ   ects our own observations of tissue samples 
stained for individual integrins and ﬂ  ow  cytometric 
analyses as well as literature data.
The collagen-binding integrins α1β1 and α2β1
Collagens are widely expressed in synovial tissue, and, 
during the course of RA, a signiﬁ   cant proportion of 
patients develop antibodies against at least one collagen 
subtype. Th   e collagens II, IX, X, and XI are restricted to 
cartilage, whereas all other forms can also be found 
within the ECM. Th   e classical collagen-binding integrins 
rely on the triple-helical structure for binding [19]. 
However, if collagen is proteolytically degraded, RGD 
sequences are exposed and other RGD-binding integrins 
can bind. In this case, ανβ3, αIIbβ3, and α5β1 can be 
activated by collagen-derived RGD sequences [20].
Four diﬀ  erent integrin combinations recognize native 
collagen: α1β1, α2β1, α10β1, and α11β1. Integrin α10β1 
is important for chondrogenesis, whereas α11β1 has a 
role in the recognition and organization of interstitial 
collagen matrices during development. During the course 
of arthritis, only α1β1 and a2β1 seem to play a role; this is 
because these are the two major collagen-binding inte-
grins in the synovial tissue. Although all of the above-
mentioned subunits bind to collagen, their respective 
speciﬁ  cities diﬀ  er for each collagen subtype; for example, 
integrin α1 preferentially binds collagen type IV.
Th  e integrin α1 was found to be expressed at the 
synovial lining and in blood vessels of arthritic joints. 
Interestingly, expression was increased compared with 
osteoarthritis and trauma controls, suggesting that the 
pro-inﬂ   ammatory milieu in RA promotes integrin α1 
synthesis [21]. However, our group also found an increase 
of this adhesion receptor on synovial ﬁ  broblasts  after 
treat  ment with cortisol [5]. An increase of α1 – in analogy 
to integrin α5, which is also upregulated by cortisol – 
poten  tially increases adhesion to collagen. Owing to 
cortisol action, the increase in integrin expres  sion is un-
coupled from integrin signaling because intra  cellular signal-
ing pathways are silenced by glucocorticoid treatment.
Lymphocytes also express integrin α1, but only synovial 
lymphocytes show increased expression of this receptor 
[22]. One important modulator for α1 levels is tumor 
necrosis factor (TNF) because anti-TNF therapy reduces 
the number of α1-positive eﬀ  ector memory T cells that 
contribute signiﬁ   cantly to inﬂ   ammation by producing 
large amounts of interferon-gamma (IFN-γ). Besides 
adhesion to collagen, α1 mediates several other eﬀ  ects, 
depending on cell type. On endothelial cells, vascular 
endothelial growth factor (VEGF) strongly upregulates 
α1, which is a prerequisite for the formation of new blood 
vessels. Inhibition of the integrin/collagen binding by 
speciﬁ  c antibodies reduced the formation of new blood 
vessels but did not alter pre-existing vasculature [23]. As 
angiogenesis is important for the progression of arthritis, 
its inhibition could be an attractive target in the therapy 
of RA. Engagement of integrin α1 on macrophages and T 
cells stimulates migra  tion and cytokine production [24]. 
Th  e role of α1 on synovial ﬁ   broblasts has not been 
elucidated yet, but studies from dermal ﬁ  broblasts 
suggest that α1 controls collagen synthesis, migration, 
and proliferation on colla  gen substrates. In a murine 
anti-collagen II antibody-induced arthritis model, 
inhibition of integrin α1 reduced cartilage degradation 
and leukocyte inﬁ  ltration, demon  strating an important 
role for this integrin in inﬂ  amma  tion [25].
Integrin α2β1 has functions similar to those of α1β1 
(for example, VEGF-induced proliferation of endothelial 
cells) but is much weaker in expression in the synovial 
tissue. Ligation of α2β1 by collagen type I or II, but not 
collagen type IV, augmented IFN-γ production in T cells. 
In contrast to CD4+ and CD8+ T cells, which upregulate 
α1β1 after activation, Th   17 cells upregulate α2β1, which 
is thought to be a co-stimulatory molecule necessary for 
IL-17 production [26]. In a model of experimental 
autoimmune encephalomyelitis, an antibody against α2 
suppressed clinical signs and central nervous system 
inﬂ  ammation because of reduced extravasation of immune 
cells. Since leukocyte inﬁ  ltrates also fuel synovial inﬂ  am-
mation, one would expect that α2 inhibition might also 
be beneﬁ  cial in the joint.
Laminin-binding integrins α3β1 and α6β1
Laminins are a major component of the basal lamina and 
usually are secreted by epithelial cells, endothelium, and 
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consisting of an α-chain, a β-chain, and a γ-chain that can 
combine to form 15 diﬀ   erent laminin isoforms [27]. 
Several integrin hetero  dimers recognize laminin as a 
ligand, but the aﬃ   nity for each laminin subtype diﬀ  ers. 
Laminin binds to integrins α3β1, α6β1, α7β1, and α6β4, 
but only the ﬁ  rst two are present in the synovial tissue. In 
the synovial  tissue, α6β1 is strongly expressed in the 
synovial lining layer by ﬁ  broblasts, whereas α3β1 is also 
expressed by lymphocytes, macrophages, and endothelial 
cells [18]. Not only the number of laminin receptors but 
also the production of laminin itself is upregulated in the 
synovial lining. Besides endothelial cells, SFs produce and 
secrete laminin, and its deposition at the synovial lining 
Figure 1. Engagement with fi  bronectin-, laminin-, or collagen-binding integrins leads to the production and secretion of 
pro-infl  ammatory factors. Binding is indicated by the arrows. Cell type, ligand (for example, fi  bronectin or fi  bronectin-derived peptides), ligand 
occupation, and integrin expression level determine the cellular response. BAFF, B-lymphocyte activating factor; CCL2, chemokine (C-C motif) 
ligand 2; IFN-γ, interferon-gamma; IL, interleukin; MMP, matrix metalloproteinase; TNF, tumor necrosis factor; VCAM-1, vascular cell adhesion protein 
1; VEGF, vascular endothelial growth factor.
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nectin, laminin promotes adhesion and proliferation of 
synovial cells and lymphocytes. Furthermore, integrin 
binding to laminin increases the expression of MMP-3 
and MMP-10, which is further augmented when trans-
forming growth factor-beta (TGF-β) is present [29]. 
Although no studies have focused on the contribution of 
laminin and its  respective integrin receptors on the 
progres  sion of RA, results from tumor research indicate 
that upregulation of α6β1 or α3β1, at least in most cases, 
increases cell invasion and metastasis. As a consequence, 
increased laminin deposition and increased integrin 
expression on synovial lining cells increase MMP 
secretion by these cells, resulting in greater joint damage 
and invasion into cartilage.
Fibronectin-binding integrins α4β1, α5β1, aνβ3, 
and αvβ5
Fibronectin is a large glycoprotein consisting of two 
mono  mers linked by disulﬁ   de bonds. Owing to alter-
native splicing, ﬁ  bronectin exists in 20 diﬀ  erent isoforms. 
Th  e molecule is folded into globular domains, each of 
which has a diﬀ  erent function. In these domains, repeat-
ing amino acid sequences form the so-called type I, II, 
and III repeats. Th  ese sequences interact with other 
proteins; for example, type I repeats bind to ﬁ  brin, and 
regions in type III repeats contain the RGD motive that 
binds integrins. Fibronectin can be divided, on the basis 
of solubility, into two classes: soluble plasma ﬁ  bronectin 
and insoluble cellular ﬁ  bronectin, the latter of which is 
organized into ﬁ   brils as a scaﬀ   old for the ECM [30]. 
Fibronectin levels are elevated in cartilage and synovial 
ﬂ   uid of patients with osteo  arthritis, whereas in RA, 
ﬁ  bronectin is highly expressed at the synovial lining and 
invading pannus [31].
About 12 integrin heterodimers bind to ﬁ  bronectin but 
only some combinations are found in the synovial tissue. 
Th  e classical ﬁ  bronectin receptor α5β1 recognizes only 
ﬁ  bronectin, whereas ανβ3 and ανβ5 also bind to other 
ECM molecules or cellular proteins. Th  e α5 integrin is 
expressed by all cells in the synovial tissue, and α5 levels 
are increased in the synovial lining layer [5]. Lymphocytes 
have been shown to attach to other synovial cells by 
binding to the ﬁ  bronectin coating on their cell surface by 
α4β1 and α5β1 and to some extent by ανβ3 integrins [32]. 
Adhesion to ﬁ   bronectin increases proliferation and 
survival of chondrocytes and protects synovial cells from 
Fas-induced apoptosis [33]. In addition, Zeisel and 
colleagues [34] found an increase of MMP-3 production 
by SFs after stimulation with a bacterial ligand of α5β1, 
suggesting that enhanced integrin ligation increases joint 
destruction in RA. Matrix-degrading enzymes in synovial 
ﬁ   broblasts are induced by small integrin-binding pep-
tides derived from the degradation of ﬁ  bronectin  and 
other ECM molecules. Werb and colleagues [7] demon-
strated that only ﬁ  bronectin-derived fragments, but not 
intact ﬁ  bronectin, increased the expression of MMP-1 
and MMP-3. Besides having a role in cell survival and 
prolifera  tion, α5β1 also regulates cytokine and growth 
factor production. In SFs, ligation of α5β1 increased 
synthesis of B-lymphocyte activating factor (BAFF) [35]. 
Increased BAFF synthesis not only promotes the 
proliferation of B cells and immunglobulin class-
switching but possibly acts as an autocrine mechanism of 
SFs to stimulate their own NF-κB activity. Besides BAFF, 
direct ligation of α5β1 induces the expression of NF-κB-
controlled genes in ﬁ  broblasts and endothelial cells. Most 
of these genes – like IL-8 and heparin-bound epidermal 
growth factor (HB-EGF) – or endothelin-1 control 
angiogenesis or inﬂ   ammation and their enhanced 
expression aggravate RA.
Naïve and memory T cells depend on binding of a4β1 
and α5β1 to ﬁ  bronectin to promote proliferation [32]. In 
this context, SFs assist in T-cell activation, as T cells bind 
to the ﬁ   bronectin coating on their surface and α4β1 
transmits co-stimulatory signals. In RA, inﬁ  ltrated T cells 
in the synovial tissue display higher surface levels of α4β1 
compared with peripheral T cells and localize to sites of 
tissue injury by binding to proteolytically degraded 
cartilage fragments. Th  e most important function of 
α4β1 on lymphocytes is adhesion to endothelium and 
subsequent transmigration to sites of injury. 
Table 1. Surface integrin levels of the predominant cell types in the rheumatoid arthritis synovium
  α1 α2 α3 α4 α5 α6 αν β1 β2 β3 β5
Synovial  fi   broblast  ++  − +(+) − +++ + +++  +++ −  ++  ?
Macrophage  + + +  +++  +++  (+)  +++  +++  ++  +++  +
Endothelium  ++  +  ++  + +++ + +++  +++ − +++ +
T  lymphocyte  (Th1)  ++  +  ++ +++  +++  +  +++  +++ ++ +++  +
Th17  cell  −  ++ ++ ++  +++ + +++  +++  ++  ?  ?
B  lymphocyte  ++ + ++  +++  +++  + ++  +++  ++ ?  ?
For most integrins, expression level data in the literature are given as ‘high’ or ‘strong’. This makes it hard to estimate integrin levels on diff  erent cell populations. We 
consulted several publications and, albeit subjectively, categorized integrin expression levels on a range from strong to weak expression (indicated by one, two, or 
three plus signs). ?, There is no available data in the literature about the expression of respective integrins.
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synovial tissue is also the mechanism that further 
supports the inﬂ  am  matory process. In RA, endothelium 
expresses high levels of VCAM-1, which acts as a binding 
partner for α4β1. After chemokine-induced activation 
and clus  ter  ing of α4β1, lymphocytes are immobilized on 
endo  thelium and transmigrate to sites of inﬂ  ammation 
[36]. Th  e important role for integrin α4β1 in RA is 
further underlined by a study by Raychaudhuri and 
colleagues [37], who show that antagonism of this 
receptor prevents inﬂ  ammation and MMP production in 
a murine model of accelerated collagen-induced arthritis.
Heterodimers containing αν are another family of 
ﬁ   bronectin-binding integrins. A polymorphism in the 
gene coding for integrin αν is associated with RA in the 
European Caucasian population [38]. Th  e integrin ανβ3 
binds ﬁ  bronectin with high aﬃ   nity and acts in concert 
with α5β1 to arrange ﬁ  bronectin matrices [39]. Besides 
binding ﬁ  bronectin, ανβ3 binds vitronectin, osteopontin, 
and bone sialoprotein with high aﬃ   nity.  Th  is integrin 
heterodimer is expressed on SFs, endothelial cells, and 
osteoclasts [40]. Not much is known about the speciﬁ  c 
role of ανβ3 on SFs, but studies from other cell systems 
and from tumor research indicate that this integrin 
promotes tissue invasion and MMP-2 production. Th  e 
major function of ανβ3 (and also of ανβ5) together with 
vascular endothelial growth factor receptor 2 (VEGF2R) 
is angiogenesis promotion [41]. Integrin ανβ3 does so by 
phosphorylating intracellular residues of the VEGR2R, 
thereby enhancing signaling of this receptor. Whereas the 
expression of ανβ3 is low on resting endothelium, levels 
increase with inﬂ  ammation and tumor angiogenesis. In 
RA, the pro-inﬂ  ammatory milieu promotes angiogenesis, 
and its inhi  bi  tion by a small-molecule αν antagonist was 
eﬃ   cacious in a rabbit model of arthritis. Whether this is 
applicable to humans remains to be seen as the 
development of vitaxin, a monoclonal antibody against 
ανβ3, was dis  continued in 2004 because the drug lacked 
eﬃ     cacy in RA. It could well be that vitaxin is only 
minimally eﬀ  ective by itself but potentiates the eﬀ  ect of 
other therapies. Th   is phenomenon is evident with cilen-
gitide, a small-peptide αν antagonist that is being 
clinically tested against a variety of cancers. Th  is  peptide 
not only inhibits angiogenesis but also increases the 
permeability of endothelium. Th   is could be exploited to 
increase the delivery of other drugs [42].
Another cell type that responds to αν antagonists is the 
osteoclast. In RA, osteoclast activity is enhanced because 
of increased RANKL (receptor activator of NF-κB ligand) 
expression, and osteoclasts are res  pon  sible for bone 
erosions in RA [43]. Th   e integrin ανβ3 increases the bone 
resorptive capacity of osteoclasts by activating several 
intracellular signaling pathways such as FAK and c-Src. 
Blockage of this integrin was protective in vitro.
The β2 integrins (CD18)
In contrast to all of the abovementioned integrin 
heterodimers, β2 integrins bind other adhesion receptors 
and are expressed exclusively on immune cells. Th  e  focus 
of this section is the αLβ2 integrin (lymphocyte function-
associated antigen 1, or LFA-1). Th   is is the major integrin 
of leukocytes and is important for tissue extravasation, 
chemotaxis, and formation of immunological synapses. 
Th  e ligand for LFA-1 is intracellular adhesion molecule 
(ICAM), which is expressed in three diﬀ  erent isoforms. 
ICAM-1 is expressed in the synovial tissue by endothelial 
cells and ﬁ   broblasts, and cell surface levels of this 
glycoprotein are increased by the action of cytokines like 
IL-1β. As the pro-inﬂ  ammatory milieu in RA also leads 
to the upregulation of αLβ2 on leukocytes, the net eﬀ  ect 
is an enhanced inﬂ  ux of immune cells in the synovial 
tissue, contributing signiﬁ   cantly to inﬂ  ammation. 
Increased cell-cell contacts between synovial ﬁ  broblasts 
and T lymphocytes lead to the activation of ﬁ  broblasts 
and result in an increased cytokine production by both 
T-cells and ﬁ  broblasts.  Th  is eﬀ   ect was dependent on 
T-cell adhesion on ﬁ   broblasts as T-lymphocyte cell 
culture supernatants failed to elicit appropriate responses 
[44]. Furthermore, αLβ2 is part of the immunological 
synapse between antigen-presenting cells and lympho-
cytes, and disruption of this interaction leads to immune 
impairments. Owing to its importance, LFA-1 is a 
suitable target for therapeutic intervention, and inhibi-
tion of this integrin by a mononclonal antibody was 
eﬃ   ca  cious in a rabbit model of RA [45]. Th  e positive 
eﬀ  ect of LFA-1 inhibition was also shown in mice treated 
with a small-molecule antagonist against this integrin. 
Animals showed reduced adhesion of T-cells to endo-
thelial cells, reduced T-cell proliferation, and decreased 
Th   1 cytokine production [46]. In humans, efalizumab, a 
monoclonal antibody against the αL subunit, was with-
drawn from the market as serious side eﬀ  ects occurred 
because of the immunosuppressive action of the drug 
[47]. A more feasible approach to dampen the activity of 
lymphocytes in RA is the inhibition of ICAM-1. Mice 
deﬁ  cient in ICAM-1 showed only minor disease activity 
in a collagen-induced arthritis model, and clinical studies 
in humans also demonstrated beneﬁ  cial  eﬀ  ects  when 
ICAM-1 was blocked by an anti-ICAM-1 monoclonal 
antibody in early RA [48,49]. Unfortunately, this antibody 
could not be administered repeatedly, as its mouse origin 
makes this antibody immunogenic, resulting in side 
eﬀ  ects such as fever and leukopenia [50].
Conclusions
During the course of RA, immune cells are recruited into 
the synovial tissue, where they produce large amounts of 
pro-inﬂ  ammatory cytokines and interact with residential 
ﬁ  broblasts and macrophages. Th  e rate of migration of 
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Page 6 of 8immune cells into the synovium is controlled by the 
expression of ICAM-1 on endothelial cells and integrin 
αLβ2 on immune cells. Th   e interaction of T lymphocytes 
(Th   1 type) with synovial ﬁ  broblasts, endothelial cells, and 
macrophages activates those cells and they start to 
produce ECM proteins, cytokines, adhesion molecules, 
and matrix-degrading enzymes. Th  e pro-inﬂ  ammatory 
milieu also increases the expression of most integrin 
subunits. Th   e combination of increased integrin expres-
sion, increased ECM deposition, and degradation along 
with high cytokine and growth factor levels in the 
synovial tissue make a perfect microenvironment for the 
perpetuation of RA. Th  e enhanced integrin signaling in 
RA is probably one cause of the high basal secretion of 
cytokines from ﬁ   broblasts and macrophages. Further-
more, increased integrin ligation enhances growth factor 
and cytokine signaling and induces the expression of 
MMPs. MMPs degrade ECM molecules, thereby 
generating small RGD peptides, which further activate 
integrins. When all the facts are taken together, it can be 
said that RA is, at least in part, an integrin-driven disease 
that can be modulated with speciﬁ  c integrin antagonists.
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